PanAmerican League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis.

Psoriatic arthritis (PsA) is chronic disease that compromise multiple domains, and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective is to generate evidence-based recommendations on the management of PsA in PANLAR countries. We used the Grading of Recommendations, Assessment, Development and Evaluation GRADEADOLOPMENT approach to adapt the 2019 recommendations of the European League Against Rheumatism (EULAR). A working group consisting of rheumatologist from various countries in Latin America, identified relevant topics for the treatment of PsA in the region. The methodology team updated the evidence and synthesized the information used to generate the final recommendations. These were then discussed and defined by a panel of 31 rheumatologists from 15 countries. Theses guidelines reports 15 recommendations addressing therapeutic targets, use of antiinflammatory agents and corticosteroids, treatment with disease-modifying antirheumatic drugs (conventional synthetic, biologic, and targeted synthetic), therapeutic failure, optimization of biological therapy, nonpharmacological interventions, and follow-up of patients with PsA. Herein, we present a set of recommendations to guide decision-making in treatment of PsA in America, based on the best evidence available, considering resources, medical expertise, and patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, health care setting on each country, and tailored evaluation of patients.